Clinical Trials Browser

Phase 1/2 × tamibarotene × Other hematologic neoplasm × Clear all

NCT06085638 2024-03-07

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic